CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 82 enrolled
Drug / intervention
Doxycycline +1 moredrug
Likely dose
Doxycycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01658995
NCT01658995Phase 3Completed
CompareCT.gov

Management of Etonogestrel Subdermal Implant-related Bleeding in US Women: a Prospective, Randomized, Placebo-controlled Trial.

Petra M. Casey·interventional·Posted Aug 7, 2012·Updated Jan 26, 2021

In Brief

A Phase 3 clinical trial evaluating Doxycycline and Placebo for ESI-related Bleeding. Completed, enrolled 82 participants across 1 site.

Detailed Summary

This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsESI-related Bleeding
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 7, 2012
Enrollment StartSep 13, 2012
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 13.9 years ago

Interventions

Doxycyclinedrug

Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.

Placebodrug

Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.